Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbisko CaymanHKSE:02256 -2.95%56 Current Ratio is 4.98 as of Dec. 2025, which is 73% below its 10-year median of 18.70. GuruFocus rates HKSE:02256 with a GF Score™ of 56/100 and a GF Value™ of HK$12.30 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,409 Biotechnology companies, Abbisko Cayman ranks better than 58.2% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Abbisko Cayman's current ratio for the quarter that ended in Dec. 2025 was 4.98.
Abbisko Cayman has a current ratio of 4.98. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Abbisko Cayman's Current Ratio or its related term are showing as below:
HKSE:02256'
s Current Ratio Range Over the Past 10 Years
Min: 4.98 Med: 18.7 Max: 35.1
Current: 4.98
During the past 7 years, Abbisko Cayman's highest Current Ratio was 35.10. The lowest was 4.98. And the median was 18.70.
HKSE:02256's Current Ratio is ranked better than 58.2% of 1409
companies
in the Biotechnology industry
Industry Median: 3.83
vs HKSE:02256: 4.98
Abbisko Cayman (HKSE:02256) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Abbisko Cayman Current Ratio Related Terms
Abbisko Cayman Current Ratio Historical Data
* Premium members only.
The historical data trend for Abbisko Cayman's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02256 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Abbisko Cayman's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Current Ratio distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbisko Cayman (HKSE:02256) has a Current Ratio of 4.98 as of Dec. 2025. This is 73% below median its historical median of 18.70. Over the past decade, Abbisko Cayman's Current Ratio has ranged from 4.98 to 35.10. According to the industry distribution chart, Abbisko Cayman ranks #589 out of 1409 companies in the Biotechnology industry, placing it in the top 41.8%.
Is Abbisko Cayman's Current Ratio too high?
Abbisko Cayman's current Current Ratio of 4.98 is 73% below median its 10-year median of 18.70. Over the past 10 years, this metric has ranged from a low of 4.98 to a high of 35.10. The Biotechnology industry median Current Ratio is 3.83. Abbisko Cayman's value of 4.98 is 30% above this industry median. Based on the distribution chart, Abbisko Cayman ranks #589 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abbisko Cayman has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abbisko Cayman ranks #589 out of 1409 companies for Current Ratio. This puts Abbisko Cayman in the upper half of its industry. The industry median Current Ratio is 3.83. Abbisko Cayman's value of 4.98 is 30% above this benchmark. Historically, Abbisko Cayman's own Current Ratio has ranged from 4.98 to 35.10 over the past decade. While the company's 10-year median is 18.70 vs. the industry median of 3.83, Abbisko Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbisko Cayman's current Current Ratio of 4.98 is 30% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbisko Cayman's current Current Ratio is 4.98, which is 73% below median its own 10-year median of 18.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (HKSE:02256) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$12.30, compared to a current price of HK$10.54 — trading 14.3% below its estimated fair value. The current Current Ratio is 4.98, which is 73% below median its 10-year median of 18.70 and 30% above the Biotechnology industry median of 3.83. Abbisko Cayman's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Abbisko Cayman (HKSE:02256), the current Current Ratio is 4.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbisko Cayman (HKSE:02256) Overvalued in 2026?
Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued.
The current stock price of HK$10.54 is trading 14.3% below its estimated GF Value™ of HK$12.30.
GuruFocus considers Abbisko Cayman to be Modestly Undervalued.
Key valuation signals for HKSE:02256:
Current Ratio: 4.98 (73% below median its 10-year median of 18.70)
GF Value™: HK$12.30 vs. price of HK$10.54 (14.3% below fair value)
Industry Position: 30% above the Biotechnology median (#589 of 1409)
No single metric tells the full story. See the HKSE:02256 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
56GF Score
Get the complete analysis for HKSE:02256
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02256 has been successfully added to your 
